留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

预防和治疗高原病药物临床用药参考

马骏 樊鹏程 张强 马慧萍 王荣 贾正平

马骏, 樊鹏程, 张强, 马慧萍, 王荣, 贾正平. 预防和治疗高原病药物临床用药参考[J]. 药学实践与服务, 2013, 31(4): 246-250. doi: 10.3969/j.issn.1006-0111.2013.04.002
引用本文: 马骏, 樊鹏程, 张强, 马慧萍, 王荣, 贾正平. 预防和治疗高原病药物临床用药参考[J]. 药学实践与服务, 2013, 31(4): 246-250. doi: 10.3969/j.issn.1006-0111.2013.04.002
MA Jun, FAN Peng-cheng, ZHANG Qiang, MA Hui-ping, WANG Rong, JIA Zheng-ping. Clinical pharmacology in the prophylaxis and treatment of high-altitude illness[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(4): 246-250. doi: 10.3969/j.issn.1006-0111.2013.04.002
Citation: MA Jun, FAN Peng-cheng, ZHANG Qiang, MA Hui-ping, WANG Rong, JIA Zheng-ping. Clinical pharmacology in the prophylaxis and treatment of high-altitude illness[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(4): 246-250. doi: 10.3969/j.issn.1006-0111.2013.04.002

预防和治疗高原病药物临床用药参考

doi: 10.3969/j.issn.1006-0111.2013.04.002
基金项目: 国家科技重大专项(军特药保密专项)(2008ZXJ09014-010).

Clinical pharmacology in the prophylaxis and treatment of high-altitude illness

  • 摘要: 本文针对乙酰唑胺、地塞米松、硝苯地平、西地那非和沙美特罗5种药物,在治疗急性高原病、高原脑水肿、高原肺水肿及伴随其他疾病情况下的高原病,就如何选择和使用这些药物进行综述。讨论了正常的给药剂量,当病人患有肾功能不全、肝功能不全、其他疾病以及存在药物相互作用情况下,就如何选择用药和剂量调整进行阐述。通过对上述问题的充分考虑,医生在救治病人时可以提高合理用药水平和治疗成功率,使病人安全愉快地在高原旅行。
  • [1] Maggiorini M, Brunner-La RHP, Peth S, et al. Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema:a randomized trial[J]. Ann Intern Med, 2006, 145:497.
    [2] Sartori C, Allemann Y, Duplain H, et al. Salmeterol for the prevention of high-altitude pulmonary edema[J]. N Engl J Med, 2002, 346:1631.
    [3] Teppema LJ, Balanos GM, Steinback CD, et al. Effects of acetazolamide on ventilatory, cerebrovascular, and pulmonary vascular responses to hypoxia[J]. Am J Respir Crit Care Med, 2007, 175:277.
    [4] Hackett PH, Roach RC. High-altitude illness[J]. N Engl J Med, 2001, 345:107.
    [5] Luks AM, Swenson ER. Medication and dosage considerations in the prophylaxis and treatment of high-altitude illness[J]. Chest, 2008, 133:744.
    [6] Pepys MB. Acetazolamide and renal stone formation[J]. Lancet, 1970, 1:837.
    [7] van Bortel L, Bohm R, Mooij J, et al. Total and free steady-state plasma levels and pharmacokinetics of nifedipine in patients with terminal renal failure[J]. Eur J Clin Pharmacol, 1989, 37:185.
    [8] Swan SK, Bennett WM. Drug dosing guidelines in patients with renal failure[J]. West J Med, 1992, 156:633.
    [9] Forgue ST, Phillips DL, Bedding AW, et al. Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics[J]. Br J Clin Pharmacol, 2007, 63:24.
    [10] Muirhead GJ, Wilner K, Colburn W, et al. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil[J]. Br J Clin Pharmacol, 2002, 53(suppl 1):21S.
    [11] Grossman EB, Swan SK, Muirhead GJ, et al. The pharmacokinetics and hemodynamics of sildenafil citrate in male hemodialysis patients[J]. Kidney Int, 2004, 66:367.
    [12] Cazzola M, Testi R, Matera MG. Clinical pharmacokinetics of salmeterol[J]. Clin Pharmacokinet, 2002, 41:19.
    [13] Dawson AM, De Groote J, Rosenthal WA, et al. The effects of diamox ammonia metabolism in liver disease[J]. Clin Sci (Lond), 1957, 16:413.
    [14] Ene MD, Roberts CJ. Pharmacokinetics of nifedipine after oral administration in chronic liver disease[J]. J Clin Pharmacol, 1987, 27:1001.
    [15] Kleinbloesem CH, van Harten J, Wilson JP, et al. Nifedipine:kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration[J]. Clin Pharmacol Ther, 1986, 40:21.
    [16] Callejas RJL, Salmeron Escobar J, Gonzalez-Calvin J, et al. Successful treatment of severe portopulmonary hypertension in a patient with Child C cirrhosis by sildenafil[J]. Liver Transpl, 2006, 12:690.
    [17] Wang YW, Lin HC, Yang YY, et al. Sildenafil decreased pulmonary arterial pressure but may have exacerbated portal hypertension in a patient with cirrhosis and portopulmonary hypertension[J]. J Gastroenterol, 2006, 41:593.
    [18] Finley DS, Lugo B, Ridgway J, et al. Fatal variceal rupture after sildenafil use:report of a case[J]. Curr Surg, 2005, 62:55.
    [19] Manchee GR, Eddershaw PJ, Ranshaw LE, et al. The aliphatic oxidation of salmeterol to alpha-hydroxysalmeterol in human liver microsomes is catalyzed by CYP3A[J]. Drug Metab Dispos, 1996, 24:555.
    [20] Swenson ER. Carbonic anhydrase inhibitors and ventilation:a complex interplay of stimulation and suppression[J]. Eur Respir J, 1998, 12:1242.
    [21] Coudon WL, Block AJ. Acute respiratory failure precipitated by a carbonic anhydrase inhibitor[J]. Chest, 1976, 69:112.
    [22] Brubaker PL. Adventure travel and type 1 diabetes:the complicating effects of high altitude[J]. Diabetes Care, 2005, 28:2563.
    [23] Stuiver PC, Goud TJ. Corticosteroids and liver amoebiasis[J]. BMJ, 1978, 2:394.
    [24] Keiser PB, Nutman TB. Strongyloides stercoralis in the immunocompromised population[J]. Clin Microbiol Rev, 2004, 17:208.
    [25] Messer J, Reitman D, Sacks HS, et al. Association of adrenocorticosteroid therapy and peptic-ulcer disease[J]. N Engl J Med, 1983, 309:21.
    [26] Wu TY, Liu JL. Alcohol and aspirin in combination with dexamethasone causes gastrointestinal bleeding at high altitude[J]. Wilderness Environ Med, 2006, 17:69.
    [27] Arruda-Olson AM, Mahoney DW, Nehra A, et al. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease:a randomized crossover trial[J]. JAMA, 2002, 287:719.
    [28] Fox KM, Thadani U, Ma PT, et al. Sildenafil citrate does not reduce exercise tolerance in men with erectile dysfunction and chronic stable angina[J]. Eur Heart J, 2003, 24:2206.
    [29] Petersen KU, Jaspersen D. Medication-induced oesophageal disorders[J]. Expert Opin Drug Saf, 2003, 2:495.
    [30] Sweeney KR, Chapron DJ, Brandt JL, et al. Toxic interaction between acetazolamide and salicylate:case reports and a pharmacokinetic explanation[J]. Clin Pharmacol Ther, 1986, 40:518.
    [31] Hill JB. Experimental salicylate poisoning:observations on the effects of altering blood pH on tissue and plasma salicylate concentrations[J]. Pediatrics, 1971, 47:658.
    [32] Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine:an update[J]. Clin Pharmacokinet, 1996, 31:198.
    [33] Tabbara KF, Al-Faisal Z, Al-Rashed W. Interaction between acetazolamine and cyclosporine[J]. Arch Ophthalmol, 1998, 116:832.
    [34] Olivesi A. Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives[J]. Biomed Pharmacother, 1986, 40:301.
    [35] Bailey DG, Dresser GK. Interactions between grapefruit juice and cardiovascular drugs[J]. Am J Cardiovasc Drugs, 2004, 4:281.
    [36] Kaplan RC, Heckbert SR, Koepsell TD, et al. Use of calcium-channel blockers and risk of hospitalized gastrointestinal tract bleeding[J]. Arch Intern Med, 2000, 160:1849.
    [37] Wu TY, Ding SQ, Liu JL, et al. High-altitude gastrointestinal bleeding:an observation in Qinghai-Tibetan railroad construction workers on Mountain Tanggula[J]. World J Gastroenterol, 2007, 13:774.
    [38] Smith M, Lin KM, Zheng YP. An open-trial of nifedipineherb interactions:nifedipine with St. John's wort, ginseng, or gingko biloba[J]. Clin Pharmacol Ther, 2001, 69:86.
    [39] Demaziere J, Fourcade JM, Busseuil CT, et al. The hazards of chloroquine self prescription in West Africa[J]. J Toxicol Clin Toxicol, 1995, 33:369.
  • [1] 赖立勇, 夏天爽, 岳小强, 辛海量.  基于网络药理学的青蒿治疗肾阴虚型糖皮质激素性骨质疏松机制研究 . 药学实践与服务, 2023, 41(11): 672-679. doi: 10.12206/j.issn.2097-2024.202204115
    [2] 董发慧, 韩金刚.  地塞米松联合右美托咪定对罗哌卡因股神经阻滞用于老年患者全膝关节置换术后镇痛效果的评价 . 药学实践与服务, 2023, 41(2): 125-129. doi: 10.12206/j.issn.2097-2024.202109020
    [3] 黄琴, 高子昭, 尼样卓玛, 索南格勒, 王荣.  高原低氧环境下硝苯地平控释片对高血压患者降压作用的临床研究 . 药学实践与服务, 2022, 40(5): 395-398. doi: 10.12206/j.issn.2097-2024.202205112
    [4] 黄粤琪, 胡静璐, 李祺, 李淼, 谢菲, 杜丽娜, 金义光.  高原肺部疾病的发病机制及治疗药物 . 药学实践与服务, 2022, 40(4): 289-295. doi: 10.12206/j.issn.1006-0111.202111025
    [5] 石志群, 高迎春, 张冬梅, 陈克明, 景临林, 马慧萍.  7-羟乙基白杨素对高原脑水肿的作用机制初探 . 药学实践与服务, 2022, 40(5): 399-402, 415. doi: 10.12206/j.issn.2097-2024.202205090
    [6] 夏天爽, 丁卢颖, 张嘉宝, 李晓瑾, 王果平, 辛海量.  啤酒花及其活性成分黄腐酚抗糖皮质激素性骨质疏松的作用研究 . 药学实践与服务, 2021, 39(3): 221-225. doi: 10.12206/j.issn.1006-0111.202102002
    [7] 熊娟, 鹿辉, 王荣, 贾正平.  超重可能是急性高山病的危险因素:一项Meta分析 . 药学实践与服务, 2018, 36(5): 433-437. doi: 10.3969/j.issn.1006-0111.2018.05.011
    [8] 熊娟, 鹿辉, 王荣, 贾正平.  急性高山病防治研究进展 . 药学实践与服务, 2017, 35(2): 97-101. doi: 10.3969/j.issn.1006-0111.2017.02.001
    [9] 付慧, 陶玉龙, 倪敏, 李冬洁, 沈甫明.  氯喹增敏地塞米松或辐射对多发性骨髓瘤细胞的杀伤作用 . 药学实践与服务, 2016, 34(3): 210-214. doi: 10.3969/j.issn.1006-0111.2016.03.005
    [10] 吴宁宁.  沙利度胺联合地塞米松治疗老年多发性骨髓瘤的疗效分析及不良反应 . 药学实践与服务, 2012, 30(6): 447-448. doi: 10.3969/j.issn.1006-0111.2012.06.014
    [11] 张玥, 韩静, 张多婷, 杨静, 孙铭, 项文娟.  中等取代度的羟丙基-β-环糊精对地塞米松的包埋特性研究 . 药学实践与服务, 2010, 28(3): 215-216,240.
    [12] 于峰.  头孢哌酮舒巴坦过敏引起急性肾功能衰竭 . 药学实践与服务, 2009, 27(5): 394-394.
    [13] 朱晓燕, 林明芳.  胸腺肽致严重过敏性休克1例 . 药学实践与服务, 2007, (1): 62-64.
    [14] 刘为义, 李作吉, 杨光.  地塞米松致白细胞增多不良反应38例分析 . 药学实践与服务, 2006, (4): 244-246.
    [15] 马一平, 王蔚红.  糖皮质激素不同给药方式对局部反应的影响 . 药学实践与服务, 2003, (2): 118-119.
    [16] 郑永红, 全东琴.  地塞米松脂质体质量控制方面的研究 . 药学实践与服务, 2001, (2): 86-88.
    [17] 娄子洋, 徐立, 汪学昭, 柴逸峰.  HPLC法测定高原康胶囊中氨茶碱、地塞米松磷酸钠和地西泮3组分的含量 . 药学实践与服务, 2001, (6): 352-353.
    [18] 刘卫, 郭卫, 张黎明, 赵志春, 苏定冯.  硝苯地平缓释片对高血压昼夜节律的作用 . 药学实践与服务, 1998, (5): 261-262.
    [19] 丁建强, 刘卫国, 张立新.  依那普利与硝苯地平治疗高血压的疗效比较 . 药学实践与服务, 1997, (6): 327-328.
    [20] 邹恒琴, 季爱民, 张忠义.  HPLC法同时测定肤康软膏中地塞米松和酮康唑的含量 . 药学实践与服务, 1994, (1): 54-55.
  • 加载中
计量
  • 文章访问数:  2650
  • HTML全文浏览量:  648
  • PDF下载量:  81
  • 被引次数: 0
出版历程
  • 收稿日期:  2012-08-22
  • 修回日期:  2012-12-18

预防和治疗高原病药物临床用药参考

doi: 10.3969/j.issn.1006-0111.2013.04.002
    基金项目:  国家科技重大专项(军特药保密专项)(2008ZXJ09014-010).

摘要: 本文针对乙酰唑胺、地塞米松、硝苯地平、西地那非和沙美特罗5种药物,在治疗急性高原病、高原脑水肿、高原肺水肿及伴随其他疾病情况下的高原病,就如何选择和使用这些药物进行综述。讨论了正常的给药剂量,当病人患有肾功能不全、肝功能不全、其他疾病以及存在药物相互作用情况下,就如何选择用药和剂量调整进行阐述。通过对上述问题的充分考虑,医生在救治病人时可以提高合理用药水平和治疗成功率,使病人安全愉快地在高原旅行。

English Abstract

马骏, 樊鹏程, 张强, 马慧萍, 王荣, 贾正平. 预防和治疗高原病药物临床用药参考[J]. 药学实践与服务, 2013, 31(4): 246-250. doi: 10.3969/j.issn.1006-0111.2013.04.002
引用本文: 马骏, 樊鹏程, 张强, 马慧萍, 王荣, 贾正平. 预防和治疗高原病药物临床用药参考[J]. 药学实践与服务, 2013, 31(4): 246-250. doi: 10.3969/j.issn.1006-0111.2013.04.002
MA Jun, FAN Peng-cheng, ZHANG Qiang, MA Hui-ping, WANG Rong, JIA Zheng-ping. Clinical pharmacology in the prophylaxis and treatment of high-altitude illness[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(4): 246-250. doi: 10.3969/j.issn.1006-0111.2013.04.002
Citation: MA Jun, FAN Peng-cheng, ZHANG Qiang, MA Hui-ping, WANG Rong, JIA Zheng-ping. Clinical pharmacology in the prophylaxis and treatment of high-altitude illness[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(4): 246-250. doi: 10.3969/j.issn.1006-0111.2013.04.002
参考文献 (39)

目录

    /

    返回文章
    返回